Document is current
Any future updates will be listed below
-
Authors
Seki, Mai
Nakano, Toshiaki https://orcid.org/0000-0001-9235-5615
Tanaka, Shigeru
Matsukuma, Yuta
Funakoshi, Kouta
Ohkuma, Toshiaki
Kitazono, Takanari
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000042284 at UMIN JapanDocuments that mention this clinical trial
Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)
https://doi.org/10.1007/s10157-023-02322-4
- License Information
-
More Information
Article History
Received: 25 July 2022
Accepted: 21 January 2023
First Online: 4 February 2023
Declarations
:
: All the authors have declared no competing interest. The drug pemafibrate used in this study is manufactured and sold by Kowa Co., Ltd. There is no conflict of interest between us and Kowa Co., Ltd.
: The present study follows “Declaration of Helsinki”, the current version adopted in 64th World Medical Association Fortaleza General Assembly Revised Edition, “Ethical guidelines for medical and health research involving human subjects” from the Japanese Ministry of Health, Labour and Welfare in 2014 at first, and “Ethical guidelines for medical and biological research involving human subjects” from the Japanese Ministry of Health, Labour and Welfare in 2022 from April 2022. And this study was approved by the Institutional Review Board of Kyushu University (approval number 20202015).
